EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
LIVONIA, Mich., March 16, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22 at the Westin New York Grand Central Hotel, and will also present at the 1st Annual H.C. Wainwright NASH Investor Event, taking place April 3, 2017, at the St. Regis Hotel in New York City.
| Oppenheimer & Company 27th Annual Healthcare Conference | ||||||||
| Date: | Tuesday, March 21 | |||||||
| Time: | 3:20pm Eastern Time | |||||||
| Location: | Track 3, Westin New York Grand Central Hotel. | |||||||
| Webcast: | https://www.veracast.com/webcasts/opco/healthcare2017/18113422476.cfm | |||||||
| H.C. Wainwright NASH Investor Event | ||||||||
| Date: | Monday, April 3 | |||||||
| Time: | 9:40am Eastern Time | |||||||
| Location: | Versailles Room, St Regis Hotel, New York City. | |||||||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
